For more than a century scientists have been searching for noninvasive technologies to peer deep inside the human body by using light. With much interests, healthcare professionals involved in the management of patients with cancer, want to see inside the body because they are interested in understanding the numerous subtle and often invisible changes to the human DNA, proteins, cells, and tissue involved in altering the body's normal biology.
For the first time, a team of…Continue
Added by Peter Hofland, PhD on September 17, 2013 at 2:00pm — No Comments
Natural Killer (NK) cells, a component of our innate immune system, are a type of lymphocyte designed to play a major role in defending our bodies in the host-rejection of both virally infected cells and cancer cells, thus protecting our bodies from harm.
Now, for the first time, scientists at Vetmeduni, the University of Veterinary Medicine, Vienna, Austria, show that NK-cell activity can be influenced by…Continue
Ductal carcinoma in situ or DCIS, a precursor of breast cancer, usually found during a mammogram as part of breast cancer screening, is the presence of abnormal cells inside a milk duct in the breast. While noninvasive and not life-threatening, it may progress to invasive breast cancer if left untreated and therefor requires treatment.…Continue
Added by Peter Hofland, PhD on September 5, 2013 at 12:30pm — No Comments
Results of a study by scientists at Johns Hopkins which was funded by the National Cancer Institute, identify a molecular marker called mitogen-inducible gene 6 or Mig6, a negative regulator of EGFR through the upregulation of the PI3K-AKT pathway. This molecular marker appears to accurately predict longer survival among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR-inhibitors. These preliminary results need further…Continue
Added by Peter Hofland, PhD on September 5, 2013 at 10:00am — No Comments
The immune system is a collection of reactions and responses protecting our bodies from harm of infection and illness caused by bacteria, viruses, fungi or parasites. The body's primary in-built protection, the
innate immunity, is always ready and prepared to act immediately. A second mechanism, the acquired immunity, learns from being exposed to diseases and creates an immune memory for future defense. These 'good' systems keep us healthy.
But a new…Continue
Added by Peter Hofland, PhD on September 5, 2013 at 9:00am — No Comments
A new multi-center trial of high dose Interleukin-2 (HD rIL-2; Aldesleukin for Injection/Proleukin®; Prometheus Laboratories Inc, San Diego, CA/Novartis Vaccines and Diagnostics, Emeryville, CA) plus vemurafenib (Zelboraf®, Genentech/Roche) therapy in patients with BRAF V600 mutation-positive…Continue
Added by Peter Hofland, PhD on May 9, 2013 at 10:00am — No Comments
Results of the ASPECCT ('763) trial, a phase III head-to-head study evaluating panitumumab (Vectibix®; Amgen Inc.) versus cetuximab (Erbitux®; ImClone LLC/Eli Lilly and Company and Bristol-Myers Squibb Company) as a single agent for the treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors (n=1,010) met its primary endpoint…Continue
Added by Peter Hofland, PhD on May 7, 2013 at 3:00pm — No Comments
Results from a behavioral research study designed to learn more about mood and physiological responses in different groups of people attempting to quit smoking published in the March 27 edition of JAMA Psychiatry shows that smokers have a higher probability of quitting smoking and a better overall cessation experience when taking varenicline compared to bupropion and to placebo or unmedicated…Continue
Added by Peter Hofland, PhD on March 27, 2013 at 4:00pm — No Comments
Food is an important factor in determining cancer incidence. Generally, vegetables rich in antioxidants and fibers tend to reduce the development of cancer, while fat-rich food may be associated with increases in breast, colon and prostate cancers. Other factors. such as a sedentary lifestyle and high calorie diet, are also associated with the development of cancer.
A major new study that tracked the diets and disease rates of nearly 380,000 people over 13 years, shows…Continue
Added by Peter Hofland, PhD on March 27, 2013 at 12:30pm — No Comments
New research published online in Clinical Chemistry, the journal of the American Association for Clinical Chemistry AACC, shows that decreased levels of vitamin D may predispose smokers to developing tobacco-related cancer. This study illustrates that simple vitamin D blood tests and supplements have the potential to improve smokers' health.
In the United States alone, cigarette smoking accounts for more deaths annually than…Continue
Added by Peter Hofland, PhD on March 15, 2013 at 11:30am — No Comments
Despite significant improvement in survival rates of patients with breast cancer, the prognosis of metastatic disease is still dismal. Cancer stem-like cells (CSC) are considered to play a role in metastatic progression of breast cancer; however, the exact pathologic role of these cancer stem-like cells is still unclear. Now, for the first time, researchers from the University of Mississippi Medical Center in Jackson, Miss, have identified…Continue
Added by Peter Hofland, PhD on February 5, 2013 at 10:30am — No Comments
Although a large majority of head and neck cancers have a deregulation of the PI3K/AKT/mTOR pathway, data recently published in Cancer Research, a journal of the American Association for Cancer Research, indicated that deregulation of this pathway does not necessarily signify that the tumor is dependent on it for survival and…Continue
Added by Peter Hofland, PhD on January 29, 2013 at 11:30am — No Comments
The phosphatidylinositol-3 kinase or PI3K signaling pathway has been identified as a valid target in a large number of cancers. It is probably one of the most important pathways in cancer metabolism and growth. Mutations in the PI3K pathway are frequent in breast cancer, ovarian and endometrial cancers, causing resistance to human epidermal growth factor receptor 2–targeted agents and, possibly, to hormonal agents as well. Available agents that affect the PI3K pathway include monoclonal…Continue
Added by Peter Hofland, PhD on January 23, 2013 at 1:30pm — No Comments
About 5% of all breast cancers are attributed to an inherited mutation in one of two cancer susceptibility genes, BRCA1 and BRCA2. Researchers how now developed a new multiple gene expression profile test was able to predict the presence of either BRCA1 or BRCA2 mutations in otherwise healthy women carrying the mutations, according to data published in Cancer Prevention Research, a…Continue
Added by Peter Hofland, PhD on January 22, 2013 at 6:00pm — No Comments
Women with breast cancer aged 35 or younger were more likely than older women to achieve a pathological complete response after neoadjuvant chemotherapy, according to data presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium, held December 4-8 in san Antonio, Texas.
“Young women with breast cancer are rare, and some data indicate that their prognosis is worse than it is for older women,” said…Continue
Added by Peter Hofland, PhD on December 6, 2012 at 2:30pm — No Comments
A large study reports that a new real-time performance tracking system, which monitors adherence to five National Quality Forum endorsed quality care metrics for breast and colon cancer, significantly improved quality standard adherence rates over a four-year period in a group of 64 cancer centers participating in the Rapid Quality Reporting System or RQRS “beta test.” Use of the system also reduced reported…Continue
Added by Peter Hofland, PhD on November 27, 2012 at 6:30pm — No Comments
The first trial of safety and toxicity shows promise for stereotactic radiosurgery as a therapeutic option for patients with localized primary renal cancer who are considered poor surgical candidates and who do not have a prior history of pelvic or abdominal radiation, according to research presented today at the American Society for Radiation Oncology’s 54th Annual Meeting (ASTRO) held in Boston, October 28 – 31,…Continue
Added by Peter Hofland, PhD on October 31, 2012 at 3:00pm — No Comments
Whole genome sequencing — spelling out all 3 billion letters in the human genome — “is an obvious and powerful method for advancing our understanding of pancreatic cancer,” according to a new study from TGen, Mayo Clinic and Scottsdale Healthcare published today.
The Translational Genomics Research Institute/TGen demonstrated that the use of WGS “represents a compelling solution to obtaining detailed molecular information on tumor biopsies in order to provide guidance for…Continue
Added by Peter Hofland, PhD on October 10, 2012 at 3:30pm — No Comments
One third of cancer patients are unaware of the fact that it is now possible to determine who is most likely to benefit from particular treatments, according to new survey data presented at ESMO 2012, the meeting of the European Society for Medical Oncology in Vienna, Austria (September 28 - October 2, 2012).…Continue
Added by Peter Hofland, PhD on October 1, 2012 at 5:00am — No Comments
A key driver behind the poor response seen with many chemotherapies and targeted agents evaluated in this setting is thought to be the stroma, which acts as a mechanical barrier to stop drug penetration and also hinder neovascularization, creating a hypoxic microenvironment. The study results of a clinical trial including TH-302, a novel anticancer agent that is converted to bromo-isophosphoramide mustard (Br-IPM), presented at ESMO 2012,…Continue
Added by Peter Hofland, PhD on September 29, 2012 at 7:00am — No Comments